These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 17898019)

  • 1. Effects of erythropoietin on advanced pulmonary vascular remodelling.
    van Albada ME; du Marchie Sarvaas GJ; Koster J; Houwertjes MC; Berger RM; Schoemaker RG
    Eur Respir J; 2008 Jan; 31(1):126-34. PubMed ID: 17898019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension.
    van Albada ME; Berger RM; Niggebrugge M; van Veghel R; Cromme-Dijkhuis AH; Schoemaker RG
    Eur J Pharmacol; 2006 Nov; 549(1-3):107-16. PubMed ID: 16978602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treprostinil in advanced experimental pulmonary hypertension: beneficial outcome without reversed pulmonary vascular remodeling.
    van Albada ME; van Veghel R; Cromme-Dijkhuis AH; Schoemaker RG; Berger RM
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):249-54. PubMed ID: 17110807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization.
    Westenbrink BD; Lipsic E; van der Meer P; van der Harst P; Oeseburg H; Du Marchie Sarvaas GJ; Koster J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    Eur Heart J; 2007 Aug; 28(16):2018-27. PubMed ID: 17576662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.
    Zhao YD; Courtman DW; Deng Y; Kugathasan L; Zhang Q; Stewart DJ
    Circ Res; 2005 Mar; 96(4):442-50. PubMed ID: 15692087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syngeneic bone marrow mononuclear cells improve pulmonary arterial hypertension through vascular endothelial growth factor upregulation.
    Yoshida H; Kitaichi T; Urata M; Kurobe H; Kanbara T; Motoki T; Kitagawa T
    Ann Thorac Surg; 2009 Aug; 88(2):418-24. PubMed ID: 19632386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of increased pulmonary blood flow in pulmonary arterial hypertension.
    van Albada ME; Schoemaker RG; Kemna MS; Cromme-Dijkhuis AH; van Veghel R; Berger RM
    Eur Respir J; 2005 Sep; 26(3):487-93. PubMed ID: 16135733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adipose-derived stem cells attenuate pulmonary arterial hypertension and ameliorate pulmonary arterial remodeling in monocrotaline-induced pulmonary hypertensive rats.
    Luo L; Lin T; Zheng S; Xie Z; Chen M; Lian G; Xu C; Wang H; Xie L
    Clin Exp Hypertens; 2015; 37(3):241-8. PubMed ID: 25271670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stem cell prevention of vascular remodeling in high flow-induced pulmonary hypertension through a paracrine mechanism.
    Luan Y; Zhang X; Kong F; Cheng GH; Qi TG; Zhang ZH
    Int Immunopharmacol; 2012 Dec; 14(4):432-7. PubMed ID: 22922316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin improves pulmonary hypertension by promoting the homing and differentiation of bone marrow mesenchymal stem cells in lung tissue.
    Zhong Z; Li K; Shen C; Ma Y; Guo L
    Hum Cell; 2024 Jan; 37(1):214-228. PubMed ID: 37968533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin Attenuates Pulmonary Vascular Remodeling in Experimental Pulmonary Arterial Hypertension through Interplay between Endothelial Progenitor Cells and Heme Oxygenase.
    van Loon RL; Bartelds B; Wagener FA; Affara N; Mohaupt S; Wijnberg H; Pennings SW; Takens J; Berger RM
    Front Pediatr; 2015; 3():71. PubMed ID: 26380246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin, but not asialoerythropoietin or carbamyl-erythropoietin, attenuates monocrotaline-induced pulmonary hypertension in rats.
    Ikarashi N; Toba K; Kato K; Ozawa T; Oda M; Takayama T; Kobayashi H; Yanagawa T; Hanawa H; Suzuki T; Nakazawa M; Nomoto M; Asami F; Higuchi M; Saito H; Aizawa Y
    Clin Exp Hypertens; 2012; 34(8):575-81. PubMed ID: 22559233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
    J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of simvastatin on rat pulmonary hypertension induced by high pulmonary blood flow and injected monocrotaline].
    Zhao L; Zhou TF; Liu HM; Li M; Dou H; Tang ZH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 38(3):463-5, 479. PubMed ID: 17593832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Ito T; Okada T; Miyashita H; Nomoto T; Nonaka-Sarukawa M; Uchibori R; Maeda Y; Urabe M; Mizukami H; Kume A; Takahashi M; Ikeda U; Shimada K; Ozawa K
    Circ Res; 2007 Sep; 101(7):734-41. PubMed ID: 17673672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels.
    Shen L; Shen J; Pu J; He B
    Cell Biochem Biophys; 2011 Sep; 61(1):23-31. PubMed ID: 21327581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of the ATP-sensitive potassium channel opener pinacidil and simvastatin on pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension.
    Jiang L; Zhou T; Liu H
    Pharmazie; 2012 Jun; 67(6):547-52. PubMed ID: 22822545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
    Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
    Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
    Li XL; Guan RJ; Li JJ
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem-cell therapy in an experimental model of pulmonary hypertension and right heart failure: role of paracrine and neurohormonal milieu in the remodeling process.
    Angelini A; Castellani C; Ravara B; Franzin C; Pozzobon M; Tavano R; Libera LD; Papini E; Vettor R; De Coppi P; Thiene G; Vescovo G
    J Heart Lung Transplant; 2011 Nov; 30(11):1281-93. PubMed ID: 21989772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.